JPMorgan Chase & Co. Increases Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $202.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price raised by equities researchers at JPMorgan Chase & Co. from $190.00 to $202.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 75.70% from the stock’s current price.

Several other research firms have also weighed in on JAZZ. Robert W. Baird cut their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. Royal Bank of Canada reduced their target price on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. Morgan Stanley lowered their price target on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a report on Friday, July 12th. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Finally, Wells Fargo & Company lowered their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.07.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $114.97 on Monday. The stock has a market cap of $7.25 billion, a PE ratio of 23.71, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58. The stock has a 50-day moving average of $108.98 and a 200-day moving average of $113.18. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 1.90. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $146.70.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Rise Advisors LLC raised its position in Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 203 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 269 shares during the period. Itau Unibanco Holding S.A. bought a new position in Jazz Pharmaceuticals in the 2nd quarter valued at about $29,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.